Analysis of Paediatric Clinical Trial Characteristics and Activity Over 23 Years-Impact of the European Paediatric Regulation on a Single French Clinical Research Center

Johanna Arnadottir; François Luc; Florentia Kaguelidou; Evelyne Jacqz-Aigrain; Collaborative CIC1426 Investigator Group

doi:10.3389/fped.2022.842480

Analysis of Paediatric Clinical Trial Characteristics and Activity Over 23 Years-Impact of the European Paediatric Regulation on a Single French Clinical Research Center

Front Pediatr. 2022 Apr 26:10:842480. doi: 10.3389/fped.2022.842480. eCollection 2022.

Authors

Johanna Arnadottir¹, François Luc¹, Florentia Kaguelidou^{1

2}, Evelyne Jacqz-Aigrain^{1

2

3}; Collaborative CIC1426 Investigator Group

Collaborators

Collaborative CIC1426 Investigator Group:
Auvin, Auvin, Delorme, Vantalon, Lecen, Eux, Carel, Tubiana, Bismuth, Baruchel, Dalle, Deschenes, Dalle, Hogan, C Dossier, Kwon, Faye, Meinzer, Melki, Houdouin, Munck, Gerardin, Hugot, Vialla, Biran, Schmitz, El Ghoneimi, Dauger, Bourat, C Alberti, S Guilmin Crepon, O Bourdon

Affiliations

¹ Clinical Investigation Center CIC1426, Hôpital Robert Debré Assistance Publique-Hôpitaux de Paris INSERM, Paris, France.
² Paris University, Paris, France.
³ Department of Paediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France.

Abstract

As unlicensed or off-label drugs are frequently prescribed in children, the European Pediatric Regulation came into force in 2007 to improve the safe use of medicinal products in the pediatric population. This present report analyzes the pediatric research trials over 23 years in a clinical research center dedicated to children and the impact of regulation. The database of trial characteristics from 1998 to 2020 was analyzed. We also searched for differences between two periods (1998-2006 and 2007-2020) and between institutional and industrial sponsors during the whole period (1998-2020). A total of 379 pediatric trials were initiated at our center, corresponding to inclusion of 7955 subjects and 19448 on-site patient visits. The trials were predominantly drug evaluation trials (n = 278, 73%), sponsored by industries (n = 216, 57%) or government/non-profit institutions (n = 163, 43%). All age groups and most subspecialties were concerned. We noted an important and regular increase in the number of trials conducted over the years, with an increased number of multinational, industrially sponsored trials. Based on the data presented, areas of improvement are discussed: (1) following ethical and regulatory approval depending on the sponsor, the mean time needed for administrative and financial agreement, validation of trial procedures allowing trial initiation at the level of the center was 6.3 and 6.5 months (periods 1 and 2, respectively) and should be reduced, (2) availability of expert research teams remain insufficient, time dedicated to research attributed to physicians should be organized and recognition of research nurses is required. The positive impact of the European Pediatric Regulation highlights the need to increase the availability of trained research teams, organized within identified multicenter international pediatric research networks.

Keywords: European paediatric regulation; drug evaluation; industrial trials; paediatric trial; public trials.